04:35 AM EDT, 10/28/2024 (MT Newswires) -- LENZ Therapeutics ( LENZ ) and Corxel Pharmaceuticals on Sunday reported positive topline data from a phase 3 clinical trial in China of LNZ100 in patients with presbyopia, a condition that results in a progressively worsening ability to see nearby objects clearly.

The companies said the study met its primary endpoint, with 74% of patients treated with LNZ100 "achieving three-lines or greater improvement at 3 hours post treatment, and maintaining their optimal distance visual acuity."

The companies said 91% of the 300 participants, aged 45 to 75 years old, noticed an improvement in their near vision.

LNZ100 was well-tolerated and no serious treatment-related adverse events occurred in the trial, LENZ Therapeutics ( LENZ ) and Corxel said.